Nuala Moran

The bad news is the world is warming faster than forecast. The good: the US is now ready to engage and Clean Tech is top of the agenda, writes Nuala Moran.

Cynics say it merely wants to curry favour with the European Union, but Intel’s revamp of its labs is a convincing model for corporate engagement in R&D, writes Nuala Moran.

Everyone’s strapped for cash – except pharma. But the latest spending spree is no more of a fix for expiring patents than botox is for ageing skin, writes Nuala Moran.

The future of early-stage bioscience firms in the UK is in doubt and funding for start-ups has virtually ceased, says a report commissioned by the UK government.

Nursing the global financial system back to health will not be the solution. Let science be the source of the green shoots of recovery, writes Nuala Moran.

As if underlining the judges’ decision, Karolinska Development, founded by Hans Wigzell, has shone light in the financial gloom, closing a big funding round.

Science is about to get back into Washington’s good books – and not before time, says Science|Business’s Nuala Moran.

The former Yugoslav Republic of Macedonia has ratified the European Patent Convention and, on 1 January, became a member of the European Patent Organisation (EPO).

The European Commission’s Directorate-General for Education and Culture has issued a call for tenders for the design and testing of a global ranking system for universities.

Graham Spittle, Vice President Software for UK, Ireland and South Africa with IBM, has been re-appointed as Chair of the UK Technology Strategy Board (TSB), for a further three years.